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Abstract 
This study presents a method of simultaneous detection of both traditional and 
newly emerged drugs of abuse in wastewater. The method is based on solid phase 
extraction (SPE) and gas chromatography- mass spectrometry (GC-MS) analysis. 
This analytical method separates 25 drugs from different classes including 
amphetamines, cathinones, tropane alkaloids, piperazines plus ketamine, 
amitriptyline, diazepam and morphine. In addition, newer compounds 
(methcathinone, mephedrone, butylone), and isomers (2-MEOPP, 4-MEOPP; 2-
FPP, 4-FPP; 3-TFMPP, 4-TFMPP) have been separated, with greater sensitivity (x 
100 order of magnitude). This work reports the detection of butylone, mephedrone, 
4-MEOPP, 2-FPP and MBZP for the first time in waste water. This suggests that 
with changes in drug use patterns, constant monitoring of waste water entering 
treatment plants should be carried out and treatment processes need to be put in 
place for their removal. 
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Introduction 
The presence of chemical pollutants in water has led to increasing public awareness 
and concern, as well as scientific interest about the effects on the environment.1,2 
Historically, pesticides and endocrine-disrupting chemicals (EDCs) have been 
reported as water pollutants.3-5 However, in recent years scientific interest in 
pharmaceutical products 6-9 and drugs of abuse as emerging pollutants has steadily 
increased.10-12 These pollutants enter the aquatic environment mainly from treated 
and untreated waste water discharge 13,14 and direct disposal as a minor route. 11  
The efficiency of the treatment process in removing pharmaceuticals has been 
investigated by several studies and results vary depending on the chemical class 
and the treatment process used.15-17 The removal efficiency range anything from 25 
% to over 90 %, which still constitutes only partial removal, and therefore these 
drugs persist in treated waste water which is ultimately discharged into surface 
water. 15 18-20  
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The knowledge that these pollutants are now being detected in water increases the 
global concern of sustainable water management. The Water Framework Directive 
(WFD) (2000/60/EC) of the European Union governs the quality of surface water 
through the Environmental Quality Standards Directive (EQSD) (2008/105/EC).21  
The EQSD (2008) acknowledges the threat to the aquatic environment that chemical 
pollution poses as this ultimately affects ecosystems and human health.  Owing to 
this the EQSD identifies various priority substances that need to be regulated with 
regard to their discharge into surface water.  On a national level, the treatment 
processes in England and Wales are regulated by the Environment Agency (EA) 
which governs the quality of waste water effluent before it is discharged.22,23  In 
addition, a Chemical Investigations Program (CIP) has been set up by the UK Water 
Industry Research (UKWIR) and the EA to investigate how efficient the current 
treatment processes are in removing some of the priority substances as stipulated 
by the EQSD. The list of priority substances has recently been expanded to include 
a few pharmaceuticals such as oestrogen and ibuprofen, which have traditionally not 
been targeted for analysis. Although, only a few pharmaceutical compounds are 
being monitored in waste water effluent by CIP, this appears to be a step in the right 
direction in recognising the changing nature of emerging pollutants. Sources of 
pharmaceutical compounds found in waste water include manufacturers, hospitals, 
and household waste.9,24 This leads to a wide spectrum of pharmaceutical-based 
pollutants not being monitored in waste water.6  
 
Investigations into the presence of pharmaceuticals in treated and untreated waste 
water was taken a step further in 200525 by measuring illicit drugs in waste water, 
where measured levels of cocaine and its metabolites were used to estimate 
consumption by a population serviced by a particular waste water treatment plant 
(WWTP).  Since then various research groups from different countries (e.g. USA, 
Belgium, Italy, Spain, U.K., Australia, Canada) have investigated illicit drugs in 
waste water and surface water.14,26-32   The main difference between the groups has 
been the classes of drugs investigated, approaches to sampling, sample 
preparation, validation studies and interpretation of results. With such data gathered 
from different countries or at different times of the year, comparisons can be made 
regarding usage patterns of drugs of abuse in different locations or seasons.28,29  
 
Moreover, sewage epidemiology as a means of estimating the consumption of drugs 
of abuse complements other forms of data such as criminal and medical records, 
drug monitoring, drug seizures and population surveys.33 In many cases the drug 
consumption figures obtained from sewage epidemiology closely match figures 
obtained from socio-epidemiological studies.34,35 Hence comparisons between the 
different forms of data can be made in order to obtain a better understanding of the 
trends in the use of drugs of abuse. One major advantage of the sewage 
epidemiology approach over socio-epidemiological methods is the production of 
real-time data since results from sewage can be obtained within hours or days while 
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socio-epidemiological studies take longer.33,36 The sewage epidemiological approach 
has even been acknowledged by The European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) as a feasible method for estimating community drug 
consumption.37 In addition, month to month or seasonal variations can be tracked. 
27,35
 Although sewage epidemiology is anonymous and generalised, it can also be 
applied to specific geographic locations or timescales  such as waste water from 
prisons38 and after a major entertainment event.39,40 
 
Although concentrations of drugs of abuse detected in surface waters are low, their 
potential risk to human and environmental health cannot be dismissed17,41 and long 
term effects of exposure are not known.   Based on the consumption levels of the 
common drugs of abuse globally and on a more local basis (U.K.)42,-44 it can be 
expected that residues of these drugs and their metabolites will be present in waste 
water influent and effluent.  Therefore these drugs and their metabolites were 
selected for this research (Figure 1).  In addition, more novel and emerging drugs of 
abuse are also included such as piperazines and cathinones.45 
 
Method  
Chemicals and reagents 
All drug standards were of analytical grade (purity >97 %), and were purchased  as 
powders or as 1 mg/ml or 0.1 mg/ml standard solutions in methanol or acetonitrile. 
Amitriptlyne hydrochloride, amphetamine-d6, amphetamine sulphate, cathinone 
hydrochloride, 1-(3-chlorophenyl)piperazeine (3-CPP), cocaine hydrochloride, 
diazepam, ecgnonine methyl ester hydrochloride hydrate (EME), ketamine, 
methcathinone hydrochloride, morphine sulphate pentahydrate,   1-(4-methylphenyl) 
piperazine (4-MPP), 1-methyl-4-benzylpiperazine (MBZP), 1-(4-methoxyphenyl) 
piperazine (4-MEOPP) were purchased from Sigma Chemical Company, U.K. 1-
Benzylpiperazine (BZP), 1-(2-methoxyphenyl) piperazine (2-MEOPP), 3,4-
methylenedioxymethamphetamine (MDMA),  piperazine, 1-(4-trifluoromethylphenyl) 
piperazine (4-TFMPP) were purchased from Fluka, U.K. Butylone hydrochloride, 4-
fluoromethamphetamine hydrochloride (4-FMA), 3-fluoromethcathinone 
hydrochloride (3-FMC) were purchased from National Measurement Institute, 
Australia. Mephedrone hydrochloride was purchased from Toronto Research 
Chemilab, Canada. Cocaine- d3, methylbenzodioxolylbutanamine hydrochloride 
(MBDB), 3,4-methylenedioxymethamphetamine-d5 and morphine- d3 were 
purchased from Cerilliant, U.K. and 1-(3-trifluoromethylphenyl) piperazine (3-
TFMPP) was purchased from Alfa Aesar, U.K.   Acetone, 35% ammonium 
hydroxide, ethyl acetate, 37% hydrochloric acid, methanol, were purchased from 
Fisher Chemical Company, U.K. and sodium sulphate was purchased from Acros, 
U.K. Pentafluoropropionic anhydride (PFPA) was purchased from Sigma Chemical 
Company, U.K.   
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Instrumentation and chromatographic conditions 
Gas Chromatography-Mass Spectrometry 
A PerkinElmer Clarus 500 Gas Chromatograph-Mass Spectrometer (GC-MS) fitted 
with a Supelco Equity TM-5 capillary column (30 m x 0.25 µm x 0.25 mm i.d.) was 
used. The carrier gas was helium at a flow rate of 1 mL/min.  
The GC oven program for quantification, repeatability and recovery studies was as 
follows: initial temperature of 50 °C, held for 2 m in, increased to 100 °C at 30 °C/min 
then increased to 280 °C at 8 °C/min and held for 5  min.  The GC–MS transfer line 
and source temperatures were set at 280 °C and 230 °C respectively. The injector 
temperature was set at 250 ºC. The mass spectrometer was operated in the electron 
impact ionization mode (+70 eV) and the MS scan (where applicable) was (m/z 50–
620). Selected ion monitoring was used for quantification and method validation.  
The total run time was 31.17 min and the solvent delay was 3.5 min. Data was 
collected, analysed and processed using TurboMass™ 5.4 GC/MS software. 
For stability studies the oven program started at 80 °C and the transfer line was set 
at 260 °C. A split ratio of 20:1 was used. All othe r parameters remained unchanged. 
  
Preparation of standards and sample 
Stock solutions as free base (1 mg/mL) were prepared in methanol or acetonitrile 
and were further diluted to individual or mixed working solutions.  All standards were 
stored at -20 °C in the dark.  Amphetamine-d 6, cocaine-d3, 3,4-
methylenedioxymethamphetamine-d5 and morphine-d3 were used as internal 
standards.   
Mixed working standards were prepared from individual stock solutions and these 
were dried and stored at -20 °C until further analy sis. For standard addition and 
recovery studies the standards were reconstituted in methanol for spiking. For 
linearity and stability studies standards were derivatised and then reconstituted in 
ethyl acetate. 
Derivatisation 
A mixed drug standard was derivatised with 0.1 mL of the PFPA:ethyl acetate (2:1 
% v/v) at 90 °C for 30 minutes, dried and then reco nstituted in ethyl acetate prior to 
analysis.  
Sample Collection and Preparation 
Waste water composite influent samples (72 hr) were collected from a treatment 
plant in Cambridge, U.K., in 1L polyethylene terephthalate (PET) containers. 
Samples were transported to the laboratory immediately after collection and vacuum 
filtered through a disposable 1000 mL capacity stericup funnel and receiver system 
with a 0.22 µm GP Millipore Express® Plus membrane (Millipore, UK).  Once 
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filtered, samples were acidified with HCl to pH 2.4 to 2.7 and stored in high density 
polyethylene (HDPE) at -20 °C and extracted after 2  months of collection.  
Extraction and recovery 
Oasis MCX® (Waters, UK) cartridges were used for solid phase extraction (SPE) of 
waste water samples. Recovery was assessed by spiking 0.1mL mixed drug 
standard (1µg/mL) into 100mL treated waste water effluent. SPE protocol is given in 
Table 1. 
INCLUDE TABLE 1 
After sample loading and rinsing, the SPE sorbents were dried under vacuum and 
eluted on the same day of analysis.  The eluents were evaporated to dryness, 
derivatised, reconstituted in ethyl acetate (0.1 mL) and analysed by GC-MS. 
Linearity, LOD, LOQ, accuracy and precision  
Instrumental linearity and range were determined by serial dilution of a mixed drug 
standard.  Derivatised mixed drug standards were prepared in ethyl acetate at 
concentrations ranging from 0.0003 to 1 µg/mL 
Intra-day repeatability of the analytical method was assessed over a short period 
under the same instrumental conditions. Six replicates of treated wastewater were 
spiked with 1 µg/mL of a mixed drug standard before extraction. 
For autosampler stability mixed drug standard with individual drugs ranging from 
15.8 to 28.8 µg/mL, except 2-FPP (40.7 µg/mL) were used. Internal standards were 
added as 1 µg/mL for MDMA-d5, and morphine-d3 and 10.2 µg/mL for cocaine-d3. 
Calibration standards and quantification 
Six point standard addition calibration graphs of PAR against concentration of 
analyte, using the internal standards: amphetamine-d6, MDMA-d5, cocaine-d3, (0.06 
µg/mL) and morphine-d3 (1.25 µg/mL) was used for quantification.46 A 500 mL, 72 hr 
composite waste water sample was diluted to 1 L and separated into 50 mL aliquots 
that were spiked with a mixed drug standards (0.0003 to 3.75 µg/mL) to enable 
matrix matching and standard addition to be carried out.  SPE extractions were 
carried out according to the method described earlier. 
Results and Discussion 
Solvent blanks were used to ensure no carryover of the analyte in between 
injections. Solvent blanks and sample matrices (spiked with internal standards only) 
were used as negative controls. Positive controls of mixed drug standard solutions 
were used to generate reference standard chromatograms/spectra (TIC and/or SIM) 
for comparison with the analytes. All analysis (including extractions) was conducted 
in triplicate unless otherwise indicated.   
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Drug standards were simultaneously analysed (Figure 1) and identified using 
retention time (Rt), retention index (RI) and mass spectra and quantified using the 
ions (m/z) as shown in Table 2. All standards at various concentrations were 
analysed individually as well as a mixed standard following PFPA derivatisation. 
Linear range, lower detection limits (LOD) and lower quantification limits (LOQ) for 
each analyte were calculated (Table 2).  All tables show the analytes in Rt order.  
Insert Figure 1 
Table 2 shows LOD and LOQs for the analytes, calculated using two methods: 
IUPAC47 and signal to noise ratio (S:N)48 The LODs and LOQs (calculated from S:N) 
from this research are lower compared to other publications (Jones-Lepp et al., 
2004). As an example the LODs for amphetamine, methamphetamine and MDMA 
have been determined as 0.14, 0.14, 0.33 pg on column respectively, in comparison 
to 1.6, 2.9 and 5.9 pg using gas chromatography-ion trap-tandem mass 
spectrometry33. LOQs from this research for amphetamine, methamphetamine, 
MDMA, cocaine and morphine have been determined as 0.33, 0.33, 1.33, 0.67, 142 
pg respectively and are significantly lower than reported values of 380, 208, 278, 18 
and 250 pg using an LC-MS-MS analysis.49  
Insert Table 2 here 
Linearity was evaluated by plots of the deviation from the regression against the log 
of concentration (ISO 17025, QA/QC) 50. The linear range (Table 2) varies from 3.0 x 
10-1 to 1.3 µg/mL for cocaine to 5.0 x 10-4 to 1.0 µg/mL for amphetamine, which is 
analyte dependant and comparable to other publications where LC-MS-MS49 was 
used. 
Instrumental intra and inter-day repeatability was assessed using relative standard 
deviation (RSD) of the detector response, PAR (Table 3) of three concentrations 
(0.005, 0.1 and 1 µg/mL). Seven replicates were analysed for intra-day and three for 
the inter-day (three separate days) study.  The intra-day relative standard deviation 
for 0.005 µg/mL ranges from 5.38% (amphetamine) to 24.19% (2-FPP); 0.1 µg/mL 
1.76% (4-FPP) to 9.99% (4-MEOPP) and 1.0 µg/mL 0.86% (4-fluoroamphetamine) 
to 8.87% (ecgonine methyl ester). The inter-day relative standard deviation for 0.005 
µg/mL ranges from 0.60% (mephedrone) to 15.99% (MBDB); 0.1 µg/mL 0.71% 
(amphetamine) to 7.57% (4-TFMPP) and 1.0 µg/mL 0.46% (methcathinone) to 
10.79% (2-MEOPP). For the lowest concentration the relative standard deviation 
ranges are higher than those at higher concentrations. Generally there is little 
difference between the intra and inter-day repeatability. This shows the inherent 
stability of the method and instrumentation. 
Autosampler stability using mixed drug standards was studied for 27 hrs. Data was 
analysed and interpreted using acceptance criteria of ±15% of target value51. A loss 
of <15% is considered acceptable, a loss of ≥15 - ≤30% is considered moderately 
stable and ≥30% loss is considered unstable. Most of the drugs were found to be 
stable. These include amitriptyline, amphetamine, BZP, butylone, cocaine, 
diazepam, 4-FMA, 3-FMC, 2 and 4-FPP, methamphetamine, mephedrone, MDMA, 
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3-TFMPP, 4-TFMPP, 4-MPP, ketamine, 2-MEOPP, 4-MEOPP, morphine, MBZP. 
However, ecgonine methyl ester was only stable for 11 hrs.   
The percentage recovery values were all above 70%, except for MDMA (66%) and 
ketamine (58%). The method of extraction was optimized to enable simultaneous 
detection of this range of drugs, including the novel drugs. Therefore when 
compared to other publications some recoveries are improved, similar or slightly 
vary to enable the method to fit all the analytes of choice in this research. In 
addition, there are many different publications using different solid phase extraction 
methods and cartridges with different recovery ranges to the choice of analytes. 
Some of the lower recoveries could be due to the reduction of sorption efficiency of 
the SPE cartridge, owing to the complex sample matrix. 6 
 
Insert Table 3 here 
The method of SPE followed by PFPA derivatisation and GC-MS analysis used in 
this research, was used to analyse real waste water samples collected from 
Cambridge U.K. Composite waste water samples (72 hrs, 25 mL x 3) were collected 
and analysed to enable matrix matched quantification using standard addition. The 
drugs detected in wastewater samples have been reported in Table 4.  These 
include popular recreational drugs such as mephedrone, buytlone, methcathinone45, 
and ketamine.  
Results also show the detection of morphine (0.3033 ± 0.033 µg/mL), amitriptyline 
(0.0111 ± 0.006 µg/mL), ketamine (0.0972 ± 0.007 µg/mL); however, these could 
have been present in the waste water through disposal of prescribed 
pharmaceuticals, hospital waste, veterinary waste as well as illegal use. It is of 
interest that higher seizures of ketamine is reported in the media as well as by police 
officers involved in drugs seizures, Initial work by this research group with 
Cambridgeshire police have already found that 8 out of 35 seized samples have 
given positive results for ketamine. 
Insert Table 4 here 
 
Conclusion 
 
In addition to the historically abused traditional drugs (amphetamine, 
methamphetamine, ketamine, amitriptyline, morphine) in this study we have 
reported the detection of newly emerging drugs of abuse in waste water. These 
include controlled cathinones (methcathinone, mephedrone, butylone) and 
piperazines (4-FPP, 2-MEOPP, 4-MEOPP, MBZP). Whilst the sample for this 
research came from Cambridgeshire, the method described can be used globally for 
waste waster analysis for the drugs outlined above. None of these drugs have any 
naturally occurring source in the U.K. and can only have been present in the water 
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as a consequence of controlled substance abuse or associated activities.  The 
authors accept that amitriptyline, morphine and ketamine have legitimate medical 
and veterinary uses and the occurrence of these drugs in this sample could have 
come from either source or a combination of the two. The data obtained in this study 
suggest that in Cambridgeshire there is a shift in drug use patterns which include 
the use of the new amphetamine type stimulant drugs (piperazines and cathinones). 
It is of particular significance that ketamine has been recently detected within street 
samples of drugs in the Cambridge U.K. area (work carried out in collaboration with 
this research group and Cambridgeshire Constabulary) and this is also reflected by 
the occurrence of ketamine in the waste water. 
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Figure 1  Total Ion Chromatogram of mixed drug standard  
(1) piperazine, (2) amphetamine, (3) methamphetamine, (4) 4-fluoromethamphetamine, (5) cathinone, (6) 3-
fluoromethcathinone, (7) methcathinone, (8) ecgonine methyl ester,  (9) mephedrone, (10) 2-
(fluorophenyl)piperazine, (11) 1-benzylpiperazine, (12) 4-(fluorophenyl)piperazine, (13) 1-(3-trifluoromethylphenyl) 
piperazine, (14) 3,4-methylenedioxymethamphetamine, (15) methylbenzodioxolylbutanamine, (16) 1-(4-
trifluoromethylphenyl) piperazine, (17) 1-(4-methylphenyl)piperazine, (18) 1-methyl-4-benzylpiperazine, (19) 1-(2-
methoxyphenyl) piperazine, (20) butylone, (21) 1-(3-chlorophenyl) piperazine, (22) 1-(4-methoxyphenyl) piperazine, 
(23) ketamine,  (24) amitriptyline, (25) cocaine,  (26) morphine, (27) diazepam, (28) heroin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
Table 1  Conditions for solid phase extraction
Parameters
SPE CARTRIDGE Oasis MCX®  (60mg,3mL)
SAMPLE pH 2.5
CONDITION 2 mL methanol, 2 x 2 mL deionised water (pH 2.5) 
FLOWRATE 5-8 mL/min
RINSE 1.5 mL deionised water (pH 2.5) 
DRYING TIME 20 mins under high vacuum
ELUTION a) 4 mL methanol (800 µL x 5);   
b) 5 x 800 µL  5% NH4OH in acetone:ethyl acetate (1:1% v/v) 
EVAPORATION 30-40 mins at 40 °C in MiVAC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Analyte Retention index Major ions LOD / pg a,b LOQ / pg a,b LOD / pg a,d LOQ / pg a, e
Amphetamine 1252 91, 118, 190 c 3.67 12.24 0.14 0.33 5.0 x 10-4 - 1.0
Methampetamine 1408 118, 160, 204 c 2.48 8.26 0.14 0.33 1.0 x 10-3 - 0.8
4-Fluoroamphetamine 1413 136, 160, 204 c 5.25 17.51 0.14 0.33 1.0 x 10-3 - 1.0
Cathinone 1415 77, 105 c  , 119 3.46 11.54 0.33 0.67 1.5 x 10-3 - 1.0
3-FMC 1421 123, 160, 204 c 2.24 7.46 0.14 2.67 1.0 x 10-1 - 1.0
Methcathinone 1431 105 c , 160, 204 6.46 21.54 0.14 0.67 2.0 x 10-3 - 1.0
Ecognine methyl ester 1438 82, 94 182 c 17.24 57.47 0.67 1.33 1.1 x 10-2 - 1.1
Mephedrone 1482 119 c , 160, 204 6.90 22.99 0.33 0.67 2.0 x 10-3 - 1.0
2-FPP 1638 150, 179, 326 c 23.86 79.52 0.67 2.67 1.5 x 10-3 - 1.0
BZP 1665 91 c , 146, 175 15.91 53.03 0.14 0.33 1.0 x 10-1 - 1.0
4-FPP 1666 150, 179, 326 c 21.35 71.18 0.67 2.67 1.5 x 10-3 - 1.0
3-TFMPP 1671  200 c , 229, 376, 28.04 93.46 0.67 2.67 2.0 x 10-3 - 0.8
MDMA 1674 160, 162, 204 c 17.64 58.79 0.33 1.33 1.0 x 10-1 - 1.0
MBDB 1804 160, 176, 218 c 22.87 76.25 0.33 0.67 2.0 x 10-3 - 0.8
4-TFMPP 1805 200 c , 229, 376 26.16 87.19 1.33 5.33 1.0 x 10-1 - 1.0
4-MPP 1811 146, 175, 322 c 21.30 71.01 2.67 5.33 1.5 x 10-3 - 1.0
MBZP 1813 105 c , 146, 189 14.82 49.40 0.33 0.67 1.0 x 10-1 - 0.8
2-MEOPP 1823 162, 191, 338 c 20.69 68.96 2.67 10.67 1.5 x 10-3 - 1.0
Butylone 1833 149 c , 160, 218 21.80 72.67 0.33 0.67 1.0 x 10-1 - 1.0
4-MEOPP 1880 162, 191, 338 c 16.97 56.57 5.33 10.67 1.5 x 10-3 - 1.0
Ketamine 1883 160 c , 312, 320 66.43 221.44 1.33 5.33 2.0 x 10-1 - 1.0
Amitriptyline 2226 58 c , 115, 202 51.70 172.33 10.67 21.33 1.0 x 10-1 - 1.0
Cocaine 2231 82 c , 105, 182 31.30 103.77 0.33 0.67 3.3 x 10-1 - 1.3
Morphine 2260 119, 146, 414 c 13.22 44.06 66.67 141.39 6.7 x 10-2 - 1.1
Diazepam 2459 256 c , 283, 285 89.20 297.33 10.67 21.33 2.0 x 10-1 - 0.8
a
 pg on column   b  n = 3    c Quantifying ion  d  calculated from 3*(S:N)  e  calculated from 10*(S:N)
Table 2  Major ions used for identification, limit of detection/quantification and linear range 
linear range / (µg/mL) b
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% recovery 
0.005b % d 0.1b % d 1.0b % d 0.005c % d 0.1c % d 1.0c % d
Amphetamine 0.146 5.38 3.37 2.70 36.79 1.33 0.193 1.80 3.69 0.71 38.24 1.50 79
Methampetamine 0.175 6.36 4.47 3.09 49.93 0.88 0.251 1.57 4.92 1.66 49.65 1.27 73
4-Fluoroamphetamine 0.159 5.79 4.31 3.10 48.62 0.86 0.229 2.90 4.58 1.25 47.79 0.99 73
Cathinone 0.069 14.31 1.20 2.69 6.97 0.70 0.075 4.24 1.32 2.73 7.39 0.49 133
Methcathinone 0.122 18.67 2.01 2.65 14.32 0.73 0.171 5.28 2.31 2.48 15.12 0.46 197
Ecgonine methyl ester 0.127 21.29 2.05 6.84 11.33 8.87 0.147 6.82 1.95 1.92 11.08 4.61 113
Mephedrone 0.189 7.77 4.31 2.91 34.20 1.09 0.263 0.60 4.92 2.46 37.04 0.47 149
2-FPP 0.026 24.19 1.10 2.55 9.29 2.73 0.048 3.09 1.04 5.24 9.60 8.11 111
BZP 0.595 8.80 4.25 6.05 34.66 2.02 0.872 4.29 4.95 3.83 41.85 9.54 75
4-FPP 0.50 1.76 9.38 2.04 0.47 4.94 9.83 8.87 148
3-TFMPP 1.01 3.33 10.53 2.56 0.93 6.88 10.70 9.38 150
MDMA 0.094 11.71 2.64 2.75 22.97 2.03 0.111 7.33 2.52 4.79 23.69 8.65 66
MBDB 0.094 9.97 2.23 2.59 21.01 2.84 0.117 15.99 2.14 4.59 21.12 8.00 77
4-TFMPP 0.87 3.76 8.94 2.24 0.81 7.57 9.26 9.62 108
4-MPP 0.11 7.22 7.19 3.66 0.09 7.34 5.75 10.21 153
MBZP 0.325 6.31 3.26 6.37 33.18 2.69 0.357 5.42 3.51 5.24 38.77 10.13 73
2-MEOPP 0.28 6.72 5.68 3.65 0.21 7.17 4.40 10.79 97
Butylone 0.389 7.97 6.18 1.80 46.69 2.95 0.448 4.46 6.26 4.68 50.93 7.26 94
3-CPP 0.13 6.46 2.18 3.18 0.11 3.14 1.81 9.48 96
4-MEOPP 0.02 9.99 4.30 3.75 3.37 9.48 94
Ketamine 0.114 8.44 1.66 2.56 12.24 1.82 0.126 5.13 1.80 3.66 13.83 9.14 58
Amitriptyline 0.455 7.56 7.15 6.55 53.92 3.24 0.559 6.92 7.31 4.92 59.31 7.00 100
Cocaine 0.310 13.37 2.66 5.68 17.25 7.61 0.387 4.27 2.59 3.83 17.89 1.56 150
Morphine 0.20 7.34 2.16 1.04 0.21 3.74 2.33 1.92 71
Diazepam 0.37 7.18 3.61 5.21 0.38 5.39 3.49 6.83 83
a
 Peak Area Ratio   b  µg/mL (n = 3)   c  µg/mL (n = 7)   d  Relative Standard Error (%) 
Analyte  Intraday PAR 
a
 repeatability  Interday PAR a  repeatability  
ND ND
ND ND ND
ND ND
ND
ND ND
ND ND
ND
ND ND
ND ND
ND ND
Table 3
  Intraday and interday repeatability and percentage recovery
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Table 4  Concentration of analytes from Cambridgeshire waste water
Analyte µg/mL ± stdev a pg a,b notes
Amphetamine 0.0230 ± 0.0147 23.0
Methampetamine 0.0715 ± 0.0401 71.5
4-Fluoroamphetamine ND
Cathinone ND
Methcathinone 0.2531 ± 0.083 253.1
Ecgonine methyl ester 0.1141 ± 0.056 114.1
Mephedrone 0.5485 ± 0.046 548.5
2-FPP ND
BZP ND
4-FPP 0.0980 ± 0.004 98.0
3-TFMPP ND
MDMA ND
MBDB ND
4-TFMPP ND
4-MPP ND
MBZP 0.0064 ± 0.0032 6.4
2-MEOPP ND
Butylone 0.0035 ±0.0023 3.5
3-CPP ND
4-MEOPP 0.0084 ± 0.006 8.4
Ketamine 0.0972 ± 0.007 97.2
Amitriptyline 0.0111 ± 0.006 11.1
Cocaine ND
Morphine 0.3033 ± 0.033 303.3
Diazepam ND
a
  n = 3   b  on column    ND = not detected  
